Severe asthma, biologic hypersensitivity and inefficacy: overcoming treatment barriers with tezepelumab
We present a 30-year-old female with severe T2-high asthma, multiple allergies, and poor disease control despite optimal therapy. She experienced an allergic reaction with omalizumab and dupilumab and had inadequate response to benralizumab. Enrolled in an early access program for tezepelumab, she showed remarkable clinical improvement, with significant FEV1 increase and FeNO reduction, allowing discontinuation of systemic corticosteroids and supplemental oxygen.
Authors
- Ana Cristina Mendes (ORCID: https://orcid.org/0000-0002-5150-6701)
- Inês Barreto (ORCID: https://orcid.org/0000-0002-1127-4811)
- Henrique Rodrigues (ORCID: https://orcid.org/0000-0002-3487-2494)
- Carlos M. Lopes (ORCID: https://orcid.org/0000-0003-2456-1200)
- M. Bragança (ORCID: https://orcid.org/0000-0003-4546-3271)
Institutions
- Hospital Universitário de Santa Maria (BR)
- Ospedale Santa Maria (IT)
- Universidade do Oeste de Santa Catarina (BR)
- Hospital de Santa Maria (PT)
Publication Details
- Journal
- Journal of Asthma
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1080/02770903.2025.2552744
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00